Concentric Capital Strategies, LP Viridian Therapeutics, Inc.\De Transaction History
Concentric Capital Strategies, LP
- $2.07 Billion
- Q4 2024
A detailed history of Concentric Capital Strategies, LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Concentric Capital Strategies, LP holds 88,527 shares of VRDN stock, worth $1.45 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
88,527Holding current value
$1.45 Million% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$78.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$75.4 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$74.2 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$63.7 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$57.8 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $654M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...